The effects of full/ fractional doses of PCV on mucosal immunology and the nasopharyngeal microbiome

Principal Investigator: Katherine Gallagher
Institution: KEMRI-Wellcome Trust Research Programme (KWTRP, Legal name ARCH)
Co-Investigators: Etienne De Villiers (KWTRP), Ifedayo Adetifa (KWTRP), Angela Karani (KWTRP), Zaydah De Laurent (KWTRP), Rose Chebet (KWTRP), Ann Karanu (KWTRP), Christian Bottomley (LSHTM), Anthony Scott (KWTRP, LSHTM), David Goldblatt (UCL), Debby Bogaert (University of Edinburgh)

Start date:  November 2019

This study seeks to identify whether there are measurable mucosal cytokine responses induced by a PCV10 booster dose at 9 months of age. This study also seeks to determine whether markers of mucosal immunology correlate with changes in the microbiome, including changes in the relative abundance of pneumococcal serotypes. In the context of the fractional dose PCV trial, a non-inferiority trial assessing full, 20% and 40% doses of PCV10 and PCV13 in a three dose schedule will be leveraged to study whether dose-dependent differences in vaccine-induced immune responses (systemic or mucosal) correlate to differences in the relative abundance of pneumococci and co-colonizers in the nasopharynx. The proposal has a broader aim to inform the target profile and performance assessments of new pneumococcal vaccines and increase our knowledge of events that may influence pneumococcal serotype replacement.

Aims and Impact

To understand whether the current pneumococcal conjugate vaccine (PCV10) stimulates mucosal cytokines and alters the nasopharyngeal microbiome in Kenyan infants.